322 related articles for article (PubMed ID: 22400044)
1. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.
Patel HJ; Modi S; Chiosis G; Taldone T
Expert Opin Drug Discov; 2011 May; 6(5):559-587. PubMed ID: 22400044
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitors as selective anticancer drugs.
Kamal A; Burrows FJ
Discov Med; 2004 Oct; 4(23):277-80. PubMed ID: 20704959
[TBL] [Abstract][Full Text] [Related]
3. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
4. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
Workman P
Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
8. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
9. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
11. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
Neckers L
Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
Porter JR; Fritz CC; Depew KM
Curr Opin Chem Biol; 2010 Jun; 14(3):412-20. PubMed ID: 20409745
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
14. Hsp90: Friends, clients and natural foes.
Verma S; Goyal S; Jamal S; Singh A; Grover A
Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
16. Potential use of heat shock protein 90 as a biomarker for the diagnosis of human diseases.
Rivas-Macho A; Romeo MV; Rackles E; Olabarria G; Falcon-Perez JM; Berganza-Granda J; Cortajarena AL; Goñi-de-Cerio F
Expert Rev Mol Diagn; 2023; 23(10):875-884. PubMed ID: 37577928
[TBL] [Abstract][Full Text] [Related]
17. TRAP1: a viable therapeutic target for future cancer treatments?
Lettini G; Maddalena F; Sisinni L; Condelli V; Matassa DS; Costi MP; Simoni D; Esposito F; Landriscina M
Expert Opin Ther Targets; 2017 Aug; 21(8):805-815. PubMed ID: 28664757
[TBL] [Abstract][Full Text] [Related]
18. Altered Hsp90 function in cancer: a unique therapeutic opportunity.
Bagatell R; Whitesell L
Mol Cancer Ther; 2004 Aug; 3(8):1021-30. PubMed ID: 15299085
[TBL] [Abstract][Full Text] [Related]
19. The stress response: implications for the clinical development of hsp90 inhibitors.
Whitesell L; Bagatell R; Falsey R
Curr Cancer Drug Targets; 2003 Oct; 3(5):349-58. PubMed ID: 14529386
[TBL] [Abstract][Full Text] [Related]
20. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
